Source - RNS
RNS Number : 6099S
Integumen PLC
12 March 2019

AIM Share Code: SKIN


12 March 2019


Integumen PLC


("Integumen" or "Company")


Share Price Movement


Integumen has noted the increase in the price of the shares of the Company over recent days.


The transformation of the Company has been swift since new management took over in August 2018.This is evident from the content of trading updates, recent laboratory expansion and CBD test results from the Company's Labskin Eco-System. Part of Integumen's growth strategy involves actively pursuing a broader portfolio of services, that contribute to increased revenues per client, through existing revenue shared collaboration and acquisition options that include, data analytics, software and biophysics integration services.


The Company is currently involved in a number of such discussions that may or may not lead to further accelerated expansion of the Company portfolio. Integumen will update the market with any new material information as appropriate in line with regulatory disclosure requirements.





Integumen plc

Gerard Brandon, CEO


+44 (0) 7340 055 643

SPARK Advisory Partners Limited

(Nominated Adviser)


Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP  (Broker)

Claire Noyce

+44 (0) 20 3764 2341


About Integumen:


Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.


The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit